Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
A Phase Ib, Multi-center, Open Label Study of Ningetinib (CT053PTSA) in Combination With Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative Who Have Progressed After EGFR TKI Therapy
Sponsor: Sunshine Lake Pharma Co., Ltd.
A PHASE1/PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Sunshine Lake Pharma Co., Ltd. and has accumulated 8 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Apr 2020 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2019 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sunshine Lake Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .